dc.creatorBORGES, Anna Paula de Sa
dc.creatorGUIDONI, Camilo Molino
dc.creatorFERREIRA, Ligia Domingues
dc.creatorFREITAS, Osvaldo de
dc.creatorPEREIRA, Leonardo Regis Leira
dc.date.accessioned2012-10-19T03:42:01Z
dc.date.accessioned2018-07-04T14:58:01Z
dc.date.available2012-10-19T03:42:01Z
dc.date.available2018-07-04T14:58:01Z
dc.date.created2012-10-19T03:42:01Z
dc.date.issued2010
dc.identifierPHARMACY WORLD & SCIENCE, v.32, n.6, p.730-736, 2010
dc.identifier0928-1231
dc.identifierhttp://producao.usp.br/handle/BDPI/20135
dc.identifier10.1007/s11096-010-9428-3
dc.identifierhttp://dx.doi.org/10.1007/s11096-010-9428-3
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1616919
dc.description.abstractObjective To evaluate the efficiency of pharmaceutical care on the control of clinical parameters, such as fasting glycaemia and glycosylated haemoglobin in patients with Type 2 Diabetes mellitus. Setting This study was conducted at the Training and Community Health Centre of the College of Medicine of Ribeirao Preto, University of Sao Paulo, Brazil. Methods A prospective and experimental study was conducted with 71 participants divided in two groups: (i) pharmaceutical care group (n=40), and (ii) the control group (n=31). The distribution of patients within these groups was made casually, and the patients were monitored for 12 months. Main outcome measure: Values for fasting glycaemia and glycosylated haemoglobin were collected. Results Mean values of fasting glycaemia in the pharmaceutical care group were significantly reduced whilst a small reduction was detected in the control group at the same time. A significant reduction in the levels of glycosylated haemoglobin was detected in patients in the pharmaceutical care group, and an average increase was observed in the control group. Furthermore, the follow-up of the intervention group by a pharmacist contributed to the resolution of 62.7% of 142 drug therapy problems identified. Conclusion In Brazil, the information provided by a pharmacist to patients with Type 2 Diabetes mellitus increases compliance to treatment, solving or reducing the Drug Therapy Problem and, consequently, improving glycaemic control.
dc.languageeng
dc.publisherSPRINGER
dc.relationPharmacy World & Science
dc.rightsCopyright SPRINGER
dc.rightsrestrictedAccess
dc.subjectBrazil
dc.subjectBrazilian Public Health System
dc.subjectCompliance
dc.subjectFasting glycaemia
dc.subjectGlycosylated haemoglobin
dc.subjectPharmacist
dc.subjectPharmaceutical Care
dc.subjectType 2 Diabetes mellitus
dc.titleThe Pharmaceutical care of patients with type 2 diabetes mellitus
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución